Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1662270 10.3389/fphar.2025.1662270 Pharmacology Correction Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research Moreland et al. 10.3389/fphar.2025.1662270 Moreland Russell 1 Arredondo Abigail 1 Dhasmana Anupam 1 2 Dhasmana Swati 1 2 Shabir Shabia 3 Siddiqua Asfia 1 Banerjee Bonny 4 Yallapu Murali M. 1 2 Behrman Stephen W. 5 Chauhan Subhash C. 1 2 Khan Sheema 1 2 * 1Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, United States 2South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX, United States 3Department of Computer Science & Engineering, National Institute of Technology, Srinagar, India 4Institute for Intelligent Systems, and Department of Electrical and Computer Engineering, University of Memphis, Memphis, TN, United States 5Department of Surgery, Baptist Memorial Medical Education, Memphis, TN, United States

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Sheema Khan, sheema.khan@utrgv.edu 13 08 2025 2025 16 1662270 08 07 2025 10 07 2025 Copyright © 2025 Moreland, Arredondo, Dhasmana, Dhasmana, Shabir, Siddiqua, Banerjee, Yallapu, Behrman, Chauhan and Khan. 2025 Moreland, Arredondo, Dhasmana, Dhasmana, Shabir, Siddiqua, Banerjee, Yallapu, Behrman, Chauhan and Khan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research by Moreland R, Arredondo A, Dhasmana A, Dhasmana S, Shabir S, Siddiqua A, Banerjee B, Yallapu MM, Behrman SW, Chauhan SC and Khan S (2025). Front. Pharmacol. 16:1543112. doi: 10.3389/fphar.2025.1543112 pancreatic cancer new-onset diabetes screening strategies biomarker discovery socio-economic factors section-at-acceptance Pharmacology of Anti-Cancer Drugs

Supplemental Figure S1 was omitted. The file has now been published.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.